On the road to immunotherapy - prospects for treating head and neck cancers with checkpoint inhibitor antibodies
On the road to immunotherapy - prospects for treating head and neck cancers with checkpoint inhibitor antibodies
Head and neck cancers (HNC) represent a heterogeneous cluster of aggressive malignancies that account for 3% of all cancer cases in the UK. HNC is increasing in frequency particularly in the developing world, which is related to changes in risk factors. Unfortunately, the mortality rate is high, which is chiefly attributed to late diagnosis at stages where traditional treatments fail. Cancer immunotherapy has achieved great successes in anti-tumor therapy. Checkpoint inhibitor (CI) antibodies enhance anti-tumor activity by blocking inhibitory receptors to drive tumor-specific T and NK cell effector responses. Since their introduction in 2011, CI antibodies have been approved for many cancer types including HNC. Here, we examine the development of CI therapies and look forward to future developments for treatment of HNC with CI therapies.
Checkpoint inhibitor, Head and neck squamous cell carcinoma, Immunotherapy, PD-1, T cells
1-12
Ward, Frank J.
ea0f07fa-2f95-4609-81a9-1a6699c874e6
Dahal, Lekh N.
1e993a7a-b007-4187-82ea-e28dd3920b66
Abu-Eid, Rasha
6fb630d8-435e-4f3d-a225-1d87939061f1
24 September 2018
Ward, Frank J.
ea0f07fa-2f95-4609-81a9-1a6699c874e6
Dahal, Lekh N.
1e993a7a-b007-4187-82ea-e28dd3920b66
Abu-Eid, Rasha
6fb630d8-435e-4f3d-a225-1d87939061f1
Ward, Frank J., Dahal, Lekh N. and Abu-Eid, Rasha
(2018)
On the road to immunotherapy - prospects for treating head and neck cancers with checkpoint inhibitor antibodies.
Frontiers in Immunology, 9 (SEP), , [2182].
(doi:10.3389/fimmu.2018.02182).
Abstract
Head and neck cancers (HNC) represent a heterogeneous cluster of aggressive malignancies that account for 3% of all cancer cases in the UK. HNC is increasing in frequency particularly in the developing world, which is related to changes in risk factors. Unfortunately, the mortality rate is high, which is chiefly attributed to late diagnosis at stages where traditional treatments fail. Cancer immunotherapy has achieved great successes in anti-tumor therapy. Checkpoint inhibitor (CI) antibodies enhance anti-tumor activity by blocking inhibitory receptors to drive tumor-specific T and NK cell effector responses. Since their introduction in 2011, CI antibodies have been approved for many cancer types including HNC. Here, we examine the development of CI therapies and look forward to future developments for treatment of HNC with CI therapies.
Text
fimmu-09-02182
- Version of Record
More information
Accepted/In Press date: 4 September 2018
e-pub ahead of print date: 24 September 2018
Published date: 24 September 2018
Keywords:
Checkpoint inhibitor, Head and neck squamous cell carcinoma, Immunotherapy, PD-1, T cells
Identifiers
Local EPrints ID: 425651
URI: http://eprints.soton.ac.uk/id/eprint/425651
ISSN: 1664-3224
PURE UUID: 3a297f3f-f430-46d8-a692-8e2292fd4394
Catalogue record
Date deposited: 31 Oct 2018 17:30
Last modified: 15 Mar 2024 22:25
Export record
Altmetrics
Contributors
Author:
Frank J. Ward
Author:
Lekh N. Dahal
Author:
Rasha Abu-Eid
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics